Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.


TSXV:ARCH - Post by User

Comment by stocksarefunon Dec 22, 2021 10:30am
81 Views
Post# 34254237

RE:RE:PFOF?

RE:RE:PFOF?So >65% of the float is insider + F/F owned, and that group keeps adding shares. We've all told our collective friends, family and anybody who would listen to buy, so I suspect the group of shareholders controlling that ~65% is probably less than 100 people tbh.

The press ARCH has gotten is great, but nobody seems to care at all. 

We suspected monster bids would come on Dec 1 after the news, but it's been a straight double black diamond ski slops since. 

I'm obviously optimistic, but extremely concerned that in the risky macro market we've been in the last 6 months, the next piece of news sharing third party review of the data will not yield the surge in share price we're hoping for.

Riverfolk shared a great reflection recently showcasing how our share price is unaffected by the news. The algos seem in control. Volume is the only thing that saves us, and we keep kicking the can on when volume 'should' show up.
<< Previous
Bullboard Posts
Next >>